According to American Cancer Society, prostate cancer is the second most common cancer among American men, with the estimated prostate cancer in the United States for 2015 are:
- About 220,800 new cases of prostate cancer.
- About 27,540 deaths from prostate cancer.
We look into the medical study, clinical results, and AHCC supplement user reviews on the use of AHCC as complementary and alternative medicine (CAM) in prostate cancer treatment:
AHCC Prostate Cancer Research #1: Clinical Study, Dosage, Results.
Source:
International Journal of Immunotherapy
Topic:
Immunomodulatory and Anticancer Effects of AHCC
Abstract:
The effects of therapy with active hemicellulose compound (AHCC) were examined in 11 cancer patients (3 with prostate cancer).
AHCC Dosage:
Patients were given AHCC (3 g/day) daily by mouth.
Results / Conclusion:
- PSA was the marker evaluated in prostatic cancer.
- All 3 patients demonstrated a significant decline in the level of PSA. There was a rapid decrease of the PSA level in two patients. They then reached normal levels of PSA at 1 to 2 months post treatment.
AHCC Prostate Cancer Research #2: Clinical Study, Medical Results.
Source:
Medical University of South Carolina, Charleston, South Carolina, USA.
Topic:
Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer
Abstract:
A prostate cancer patient whose cancer had spread to his bones and who had not responded to androgen deprivation therapy, was treated with AHCC mushroom supplement.
Results / Conclusion:
- The patient’ PSA levels dropped from 69.3 ng/ml to 3.35 ng/ml (95% reduction) in June 2007.
- Further follow-up demonstrated that his PSA dropped to a nadir of 1.5 ng/ml by August 2007, with his PSA level remained low at 2.57 ng/ml in November 2007.
AHCC Prostate Cancer Research #3: Clinical Study, Dosage, Results.
Source:
Japanese Journal of Clinical Oncology
Topic:
Dietary Administration of Mushroom Mycelium Extracts in Patients with Early Stage Prostate Cancers Managed Expectantly: A Phase II Study
Abstract:
74 patients with early prostate cancer were given mushroom mycelium extract AHCC for 6 months, to assess the efficacy and safety of dietary supplements in patients with early stage prostate cancers who are managed expectantly.
AHCC Dosage:
4.5 g/day
Results / Conclusion:
- 1 out of 74 patients (1.4%) displayed PSA levels that were decreased by 50% or more after AHCC treatment. Changes in PSA levels before and after treatment were substantially stable.
- In patients exhibiting strong anxiety before the start of the trial, the anxiety significantly decreased after 6 months of treatment.
- There were no complications related to the safety of AHCC, and only 1 out of the 74 patients discontinued AHCC due to side effects (diarrhea).
Best AHCC Supplement Brands Overview
| Brand | ImmunoKinoko | Kinoko Platinum | Kinoko Gold AHCC | NOW Foods AHCC |
| Product Image |  |  |  |  |
| Manufacturer | Quality of Life | Quality of Life | Quality of Life | NOW Foods |
| Learn More |  | | | |
Prostate Cancer: AHCC Supplement User Reviews and Results